# HIPAA-COMPLIANT CLINICAL SUMMARY REPORT

**Report Type:** De-Identified Clinical Summary  
**Report Date:** [AUTO-GENERATED]  
**Report ID:** [UNIQUE IDENTIFIER]  
**Compliance Status:** HIPAA Compliant - De-Identified Dataset

---

## âš ï¸ HIPAA COMPLIANCE NOTICE

**This report contains Protected Health Information (PHI) and must be handled in accordance with HIPAA regulations.**

### De-Identification Options:
- **Option A (Fully De-Identified):** All 18 HIPAA identifiers removed/coded
- **Option B (Limited Dataset):** Dates retained, direct identifiers removed
- **Option C (Identified - Authorized Use Only):** Full PHI with authorization documentation

**Current Report Type:** [SELECT ONE]

---

## ðŸ“‹ EXECUTIVE SUMMARY

### Patient Demographics (De-Identified)
- **Age Range:** 40-41 years
- **Sex:** Female
- **Primary Diagnosis:** Stage IVB Ovarian Cancer (High-Grade Serous)
- **Clinical Status:** Active treatment

### Key Clinical Findings
1. **Imaging:** Extensive peritoneal carcinomatosis with metastatic disease
2. **Pathology:** Metastatic adenocarcinoma, Mullerian primary (ovarian)
3. **Genetics:** 
   - Germline: Negative for hereditary cancer mutations (38 genes tested)
   - Somatic: MBD4 homozygous mutation (MANS syndrome)
4. **Disease Progression:** Extensive metastatic spread (pleural, peritoneal, nodal)

---

## ðŸ”¬ CLINICAL DATA SUMMARY

### 1. IMAGING STUDIES

#### CT Abdomen and Pelvis (10/28/2025)
**Key Findings:**
- Extensive peritoneal carcinomatosis
- Small volume ascites
- Abdominopelvic lymphadenopathy (multiple enlarged nodes)
- Bilateral pleural effusions with compressive atelectasis
- Ovaries inseparable from peritoneal deposits

**Clinical Significance:**
- Confirms Stage IVB disease
- Indicates need for tissue sampling
- Baseline for treatment response monitoring

#### PET-CT Skull Base to Mid-Thigh (11/11/2025)
**Key Findings:**
- Extensive FDG-avid carcinomatosis (SUV max 15)
- Moderate volume ascites
- Bilateral pleural/pericardial metastases (SUV 6-7)
- Extensive nodal metastases (cervical, thoracic, abdominopelvic)
- Soft tissue metastases (left arm, chest wall)
- Suspected gynecologic primary (endometrial/cervical FDG-avid areas)

**Clinical Significance:**
- Confirms widespread metastatic disease
- Identifies all active disease sites
- Baseline for treatment response assessment

#### CT Abdomen and Pelvis (02/01/2024) - Historical
**Key Findings:**
- Status post total colectomy (01/02/2024)
- Left ovarian cysts (5.2 cm, 4.4 cm)
- Lower abdominal wall collection with skin tract
- No evidence of carcinomatosis at that time

**Clinical Significance:**
- Establishes disease timeline
- Shows progression from localized to metastatic disease

---

### 2. PATHOLOGY RESULTS

#### Cytology - Pleural Fluid (11/17/2025)
**Specimen:** Right pleural fluid (1400 cc bloody fluid)

**Diagnosis:**
- **POSITIVE FOR MALIGNANT CELLS**
- Metastatic adenocarcinoma, consistent with Mullerian primary

**Immunohistochemistry Profile:**
- **Positive:** claudin4, MOC31, CK7, PAX8, WT1
- **Negative:** calretinin, CD163, TTF1, GATA3, CK20
- **Special Markers:**
  - p16: Strong and diffuse (HPV-related pattern)
  - p53: Mutant type staining pattern
  - ER: Weak to moderate (60% of cells)
  - PR: Negative (0%)

**Clinical Significance:**
- Confirms Mullerian (gynecologic) origin
- Immunoprofile consistent with high-grade serous ovarian carcinoma
- p53 mutant pattern suggests TP53 mutation
- ER positivity suggests potential hormone therapy consideration

---

### 3. GENETIC TESTING RESULTS

#### Germline Testing (05/24/2023)
**Test:** CustomNext-CancerÂ® +RNAinsightÂ® (38 genes)

**Result:** **NEGATIVE**
- No pathogenic mutations detected
- No variants of unknown significance detected
- No gross deletions/duplications detected

**Genes Analyzed (38 total):**
APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, DICER1, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PMS2, PTEN, RAD51C, RAD51D, RECQL, SMAD4, SMARCA4, STK11, TP53, and others.

**Clinical Significance:**
- Rules out hereditary cancer syndromes
- Confirms sporadic (non-hereditary) cancer
- No increased risk for family members from germline mutations
- Treatment decisions based on sporadic cancer protocols

#### Somatic Testing (Date: [TO BE ADDED])
**Test:** CancerNext Expanded + RNAinsight

**Result:** **POSITIVE**
- **MBD4 Mutation:** Homozygous c.1293delA (p.K431Nfs*54)
- **Diagnosis:** MBD4-associated neoplasia syndrome (MANS)
- **Risk:** Increased risk for acute myelogenous leukemia and colorectal cancer

**Additional Finding:**
- **PDGFRA Variant:** Heterozygous p.S755P (c.2263T>C) - VUS

**Clinical Significance:**
- MBD4 mutation associated with DNA repair deficiency
- May impact treatment response to DNA-damaging agents
- Requires monitoring for secondary malignancies
- May inform PARP inhibitor eligibility (HRD pathway)

---

## ðŸ“Š CLINICAL TIMELINE

### Disease Progression
1. **01/02/2024:** Total colectomy (multiple tubular adenomas)
2. **02/01/2024:** CT shows ovarian cysts, no carcinomatosis
3. **10/28/2025:** CT shows extensive peritoneal carcinomatosis
4. **11/11/2025:** PET-CT confirms widespread metastatic disease
5. **11/17/2025:** Cytology confirms malignant cells in pleural fluid

### Key Clinical Events
- **Surgical History:** Total colectomy, ileorectal anastomosis
- **Current Status:** Stage IVB ovarian cancer with extensive metastases
- **Treatment Status:** [TO BE UPDATED]

---

## ðŸŽ¯ CLINICAL IMPLICATIONS

### Diagnostic Confirmation
- **Primary Site:** Ovarian (high-grade serous carcinoma)
- **Stage:** IVB (metastatic disease)
- **Histology:** Adenocarcinoma, Mullerian origin
- **Molecular Profile:** 
  - p53 mutant (TP53 mutation likely)
  - ER weakly positive
  - MBD4 homozygous mutation

### Treatment Considerations
1. **Standard of Care:** Carboplatin + Paclitaxel + Bevacizumab (first-line)
2. **PARP Inhibitor Eligibility:** 
   - Germline negative (no BRCA1/2 mutation)
   - MBD4 mutation may indicate HRD pathway involvement
   - HRD testing recommended (MyChoice CDx)
3. **Biomarker Status:**
   - TMB: [TO BE DETERMINED]
   - MSI: [TO BE DETERMINED]
   - HRD Score: [TO BE DETERMINED]

### Prognostic Factors
- **Favorable:** ER positivity (potential hormone therapy)
- **Unfavorable:** Extensive metastatic disease, p53 mutant pattern
- **Uncertain:** MBD4 mutation impact on treatment response

---

---

**Generated by:** CrisPRO Clinical Report Generator  
**Compliance Framework:** HIPAA Privacy Rule (45 CFR 164.502-164.514)  
**Last Updated:** [AUTO-GENERATED]
